Saturday, March 21, 2015

Aducanumab can slow the progress of Alzheimer

Aducanumab can slow the progress of Alzheimer

Aducanumab, an antibody show benefits in patient who are administered with it in very earliest stage of Alzheimer. In a very small volunteer set of 166 patients, a trial for testing Aducanumab efficiency in combating dementia was tested. The trial results were presented at the International Conference on Alzheimer’s and Parkinson’s Diseases andRelated Neurological Disorders in Nice, France.

At one end, a small sample set is not very encouraging sign but the fact that there are no reliable alternative as drugs to halt or even slow the progress of dementia – of which Alzheimer’s is the most common type – means that any positive results will be greeted with enthusiasm.

The higher the dose of drug the patient was given, the greater the reduction. Tests also showed that those people who took the drug had a slower rate of mental decline than those who did not – although the trial was not set up primarily to see whether there was any effect on cognition.

Biogen Idec, the company that made the drug, announced it would be moving quickly into large-scale trials which will involve hundreds, if not thousands, of people.